{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031881","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.091266+00:00","generated_at":"2026-05-31T09:32:13.511413+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProPhase Labs Q2 revenue falls 81% to $2.5M; net loss $(0.33) per share; eyes H2 growth","bullets":["Net revenue $2.5M vs $13.2M YoY; net loss $6.2M ($0.33 per share) vs $3.4M ($0.20) in Q2 2023.","COVID-19 testing revenue zero (126K tests in prior year); overall gross margin negative 19.2%.","Pharmaloz projects $14-16M revenue and >$5M pre-tax profit over next 12 months; exploring potential sale.","Nebula Genomics launching revamped DTC product 'DNA Complete' with influencer marketing campaign.","Cash and equivalents $2.4M; working capital $16.1M; expects significant sequential revenue growth in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031881","json":"https://secwatch.observer/filing/0001493152-24-031881.json","markdown":"https://secwatch.observer/filing/0001493152-24-031881.md","text":"https://secwatch.observer/filing/0001493152-24-031881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315224031881/0001493152-24-031881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315224031881/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:32:13.511413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}